Celltrion Pharm Stock EBITDA
| 068760 Stock | KRW 62,400 900.00 1.46% |
Celltrion Pharm fundamentals help investors to digest information that contributes to Celltrion Pharm's financial success or failures. It also enables traders to predict the movement of Celltrion Stock. The fundamental analysis module provides a way to measure Celltrion Pharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Celltrion Pharm stock.
Celltrion |
Celltrion Pharm Company EBITDA Analysis
Celltrion Pharm's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Celltrion Pharm EBITDA | 42.8 B |
Most of Celltrion Pharm's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Celltrion Pharm is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Celltrion Pharm reported earnings before interest,tax, depreciation and amortization of 42.8 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The ebitda for all Republic of Korea stocks is notably lower than that of the firm.
Celltrion EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Celltrion Pharm's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Celltrion Pharm could also be used in its relative valuation, which is a method of valuing Celltrion Pharm by comparing valuation metrics of similar companies.Celltrion Pharm is currently under evaluation in ebitda category among its peers.
Celltrion Fundamentals
| Return On Equity | 0.0891 | |||
| Return On Asset | 0.0341 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.11 % | |||
| Current Valuation | 5.87 T | |||
| Shares Outstanding | 34.05 M | |||
| Shares Owned By Insiders | 57.79 % | |||
| Shares Owned By Institutions | 6.75 % | |||
| Price To Earning | 62.82 X | |||
| Price To Sales | 8.22 X | |||
| Revenue | 398.74 B | |||
| Gross Profit | 72.93 B | |||
| EBITDA | 42.8 B | |||
| Net Income | 34.58 B | |||
| Cash And Equivalents | 80.19 B | |||
| Cash Per Share | 815.33 X | |||
| Total Debt | 39.4 B | |||
| Debt To Equity | 0.64 % | |||
| Current Ratio | 1.25 X | |||
| Book Value Per Share | 10,914 X | |||
| Cash Flow From Operations | 93.15 B | |||
| Target Price | 136000.0 | |||
| Number Of Employees | 29 | |||
| Beta | 0.23 | |||
| Market Capitalization | 2.1 T | |||
| Total Asset | 637.88 B | |||
| Retained Earnings | 30.6 B | |||
| Working Capital | 58.94 B | |||
| Current Asset | 144.21 B | |||
| Current Liabilities | 85.27 B | |||
| Z Score | 31.8 | |||
| Net Asset | 637.88 B |
About Celltrion Pharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Celltrion Pharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Celltrion Pharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Celltrion Pharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Celltrion Pharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Celltrion Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Celltrion Pharm will appreciate offsetting losses from the drop in the long position's value.Moving together with Celltrion Stock
Moving against Celltrion Stock
| 0.84 | 122870 | YG Entertainment | PairCorr |
| 0.79 | 041510 | SM Entertainment | PairCorr |
| 0.74 | 003535 | Hanwha InvestmentSecuri | PairCorr |
| 0.74 | 012330 | Hyundai Mobis | PairCorr |
| 0.65 | 032640 | LG Uplus | PairCorr |
The ability to find closely correlated positions to Celltrion Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Celltrion Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Celltrion Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Celltrion Pharm to buy it.
The correlation of Celltrion Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Celltrion Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Celltrion Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Celltrion Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Celltrion Stock
Celltrion Pharm financial ratios help investors to determine whether Celltrion Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Celltrion with respect to the benefits of owning Celltrion Pharm security.